Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 20 | 2022 | 493 | 4.210 |
Why?
|
| Isometric Contraction | 15 | 2022 | 118 | 3.080 |
Why?
|
| Muscle, Skeletal | 21 | 2020 | 638 | 2.590 |
Why?
|
| Pain Threshold | 9 | 2022 | 89 | 2.550 |
Why?
|
| Muscle Fatigue | 5 | 2022 | 77 | 2.010 |
Why?
|
| Bicycling | 5 | 2019 | 41 | 1.850 |
Why?
|
| Myalgia | 5 | 2020 | 20 | 1.810 |
Why?
|
| Pain | 7 | 2019 | 258 | 1.730 |
Why?
|
| Pain Perception | 3 | 2022 | 17 | 1.680 |
Why?
|
| Caffeine | 3 | 2016 | 39 | 1.430 |
Why?
|
| Young Adult | 27 | 2025 | 2804 | 1.390 |
Why?
|
| Chronic Pain | 2 | 2022 | 62 | 1.380 |
Why?
|
| Muscle Contraction | 5 | 2018 | 171 | 1.360 |
Why?
|
| Oxygen Consumption | 9 | 2019 | 181 | 1.340 |
Why?
|
| Mouthwashes | 2 | 2022 | 4 | 1.320 |
Why?
|
| Torque | 7 | 2018 | 91 | 1.080 |
Why?
|
| Male | 38 | 2025 | 13772 | 1.050 |
Why?
|
| Quadriceps Muscle | 5 | 2018 | 61 | 1.000 |
Why?
|
| Pain Measurement | 7 | 2017 | 172 | 1.000 |
Why?
|
| Muscle Strength | 8 | 2020 | 230 | 1.000 |
Why?
|
| Ginger | 3 | 2010 | 3 | 0.970 |
Why?
|
| Performance-Enhancing Substances | 2 | 2016 | 4 | 0.960 |
Why?
|
| Central Nervous System Stimulants | 2 | 2016 | 32 | 0.950 |
Why?
|
| Adult | 28 | 2025 | 7922 | 0.910 |
Why?
|
| Physical Endurance | 2 | 2016 | 91 | 0.850 |
Why?
|
| Humans | 44 | 2025 | 28585 | 0.820 |
Why?
|
| Female | 35 | 2025 | 15472 | 0.800 |
Why?
|
| Muscular Diseases | 2 | 2015 | 12 | 0.800 |
Why?
|
| Electric Stimulation | 5 | 2018 | 255 | 0.770 |
Why?
|
| Carbohydrates | 2 | 2022 | 17 | 0.770 |
Why?
|
| Recruitment, Neurophysiological | 3 | 2018 | 13 | 0.730 |
Why?
|
| Double-Blind Method | 8 | 2025 | 421 | 0.710 |
Why?
|
| Evoked Potentials, Motor | 2 | 2018 | 22 | 0.700 |
Why?
|
| Phytotherapy | 2 | 2010 | 22 | 0.620 |
Why?
|
| Athletes | 1 | 2019 | 70 | 0.600 |
Why?
|
| Cross-Over Studies | 6 | 2025 | 137 | 0.590 |
Why?
|
| Volition | 1 | 2018 | 6 | 0.570 |
Why?
|
| Hypesthesia | 1 | 2016 | 3 | 0.500 |
Why?
|
| Lower Extremity | 2 | 2017 | 85 | 0.490 |
Why?
|
| Electromyography | 6 | 2020 | 176 | 0.470 |
Why?
|
| Pressure | 1 | 2015 | 90 | 0.460 |
Why?
|
| Recovery of Function | 1 | 2015 | 122 | 0.440 |
Why?
|
| Resistance Training | 3 | 2022 | 212 | 0.440 |
Why?
|
| Arthralgia | 1 | 2013 | 7 | 0.410 |
Why?
|
| Anaerobic Threshold | 1 | 2012 | 19 | 0.390 |
Why?
|
| Analgesics | 1 | 2010 | 38 | 0.340 |
Why?
|
| Body Composition | 2 | 2022 | 266 | 0.330 |
Why?
|
| Range of Motion, Articular | 4 | 2017 | 63 | 0.330 |
Why?
|
| Regional Blood Flow | 4 | 2020 | 164 | 0.320 |
Why?
|
| Analysis of Variance | 3 | 2016 | 391 | 0.290 |
Why?
|
| Vibration | 3 | 2022 | 78 | 0.280 |
Why?
|
| Time Factors | 5 | 2017 | 1600 | 0.280 |
Why?
|
| Adolescent | 6 | 2020 | 3165 | 0.260 |
Why?
|
| Exercise Test | 4 | 2019 | 249 | 0.250 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2025 | 5 | 0.240 |
Why?
|
| Hypovolemia | 1 | 2025 | 5 | 0.240 |
Why?
|
| Blood Flow Velocity | 4 | 2025 | 66 | 0.240 |
Why?
|
| Fluconazole | 1 | 2025 | 12 | 0.240 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2025 | 35 | 0.240 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2015 | 8 | 0.240 |
Why?
|
| Oxygen | 2 | 2016 | 234 | 0.230 |
Why?
|
| Bone Density | 2 | 2023 | 101 | 0.230 |
Why?
|
| Rest | 1 | 2025 | 96 | 0.230 |
Why?
|
| Physical Exertion | 3 | 2020 | 104 | 0.230 |
Why?
|
| High-Intensity Interval Training | 1 | 2023 | 9 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 1 | 2025 | 224 | 0.210 |
Why?
|
| Dietary Supplements | 2 | 2020 | 265 | 0.210 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 10 | 0.190 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2017 | 74 | 0.190 |
Why?
|
| Hyperalgesia | 1 | 2022 | 16 | 0.190 |
Why?
|
| Ice | 1 | 2022 | 9 | 0.190 |
Why?
|
| Leg | 2 | 2020 | 134 | 0.190 |
Why?
|
| Shoes | 1 | 2021 | 9 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 988 | 0.180 |
Why?
|
| Foot | 1 | 2021 | 23 | 0.180 |
Why?
|
| Fatigue | 1 | 2022 | 64 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2022 | 273 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2008 | 834 | 0.170 |
Why?
|
| Elbow | 2 | 2010 | 15 | 0.170 |
Why?
|
| Hand Strength | 1 | 2020 | 38 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 782 | 0.160 |
Why?
|
| Functional Laterality | 1 | 2020 | 64 | 0.160 |
Why?
|
| Knee | 2 | 2017 | 25 | 0.160 |
Why?
|
| Collagen | 1 | 2020 | 156 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 202 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 301 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2020 | 458 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 89 | 0.140 |
Why?
|
| Ischemia | 2 | 2017 | 83 | 0.140 |
Why?
|
| Pyramidal Tracts | 1 | 2018 | 8 | 0.140 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 182 | 0.140 |
Why?
|
| Femoral Artery | 1 | 2017 | 58 | 0.130 |
Why?
|
| Hand | 1 | 2017 | 26 | 0.130 |
Why?
|
| Tourniquets | 1 | 2017 | 15 | 0.130 |
Why?
|
| Microcirculation | 1 | 2017 | 113 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2017 | 37 | 0.130 |
Why?
|
| Neoplasms | 2 | 2017 | 857 | 0.130 |
Why?
|
| Microvessels | 1 | 2017 | 86 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2017 | 47 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2016 | 58 | 0.120 |
Why?
|
| Physical Stimulation | 1 | 2016 | 72 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2017 | 84 | 0.120 |
Why?
|
| Hypoxia | 1 | 2016 | 90 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2017 | 355 | 0.120 |
Why?
|
| Hot Temperature | 1 | 2016 | 87 | 0.120 |
Why?
|
| Hypertension | 1 | 2017 | 309 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 328 | 0.100 |
Why?
|
| Adaptation, Physiological | 2 | 2017 | 173 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 30 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 77 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2010 | 42 | 0.080 |
Why?
|
| Arm | 1 | 2010 | 37 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 167 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 223 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 2009 | 57 | 0.080 |
Why?
|
| Diet | 1 | 2010 | 232 | 0.070 |
Why?
|
| Radio Waves | 1 | 2008 | 21 | 0.070 |
Why?
|
| Radial Artery | 1 | 2008 | 21 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 770 | 0.070 |
Why?
|
| Random Allocation | 1 | 2007 | 151 | 0.070 |
Why?
|
| Myoglobin | 2 | 2017 | 33 | 0.060 |
Why?
|
| Heart Rate | 1 | 2008 | 380 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 61 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2017 | 118 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 113 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 732 | 0.060 |
Why?
|
| Lower Body Negative Pressure | 1 | 2025 | 5 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2025 | 50 | 0.060 |
Why?
|
| Middle Aged | 4 | 2019 | 7310 | 0.060 |
Why?
|
| Smoking | 1 | 2008 | 476 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2023 | 24 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2017 | 5 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2023 | 78 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2023 | 129 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 84 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 44 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 100 | 0.050 |
Why?
|
| Thigh | 2 | 2015 | 39 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 82 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 185 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2020 | 221 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 467 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1272 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 2402 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 17 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 115 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2017 | 31 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 31 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 44 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2017 | 61 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 40 | 0.030 |
Why?
|
| Aged | 2 | 2017 | 5525 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 32 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 203 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 302 | 0.020 |
Why?
|
| Hemorheology | 1 | 2008 | 7 | 0.020 |
Why?
|
| Forearm | 1 | 2008 | 39 | 0.020 |
Why?
|
| Vasodilation | 1 | 2008 | 115 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 2045 | 0.020 |
Why?
|